Form 4: Veracyte Director Eliav Barr Receives Equity Grant of 9,321 Restricted Stock Units

Veracyte, Inc. Director Eliav Barr was granted 9,321 Restricted Stock Units (RSUs) on June 18, 2025, as part of his compensation, increasing his total beneficial ownership to 51,189 shares.

Summary

• Eliav Barr, a Director of Veracyte, Inc. (VCYT), acquired 9,321 shares of Common Stock through a Restricted Stock Unit (RSU) grant.
• The transaction occurred on June 18, 2025, with an acquisition price of $0 per unit, typical for RSU grants.
• Following this transaction, Mr. Barr's total beneficial ownership of Veracyte Common Stock increased to 51,189 shares.
• The granted RSUs are scheduled to vest in full on the first anniversary of the grant date (June 18, 2026) or immediately prior to the Company's next annual meeting of stockholders, whichever is earlier.
• Additionally, the RSUs will vest in full immediately in the event of a change in control of Veracyte, Inc.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates standard director compensation and aligns insider interests with shareholders, without any negative implications.

Positives

• The grant of Restricted Stock Units to a director aligns the director's financial interests with those of the shareholders, encouraging long-term value creation.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Future Outlook

The granted Restricted Stock Units are set to vest on the first anniversary of the grant date (June 18, 2026) or immediately prior to the Company's next annual meeting of stockholders, if earlier. Full vesting will also occur upon a change in control of the Issuer.

Industry Context

This Form 4 filing reports a routine insider transaction, specifically an equity grant to a director. Such grants are a common component of executive and director compensation packages across various industries, designed to align leadership interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a standard practice for non-employee director compensation in publicly traded companies across the biotechnology and diagnostics sectors, similar to companies like Exact Sciences Corp. (EXAS) or Guardant Health, Inc. (GH).
• The vesting schedule, tied to an anniversary date or the next annual meeting, is also a common structure for director RSU grants, ensuring continued engagement and alignment over a defined period.
• The provision for accelerated vesting upon a change in control is a typical clause in equity compensation plans, providing protection and incentivizing directors during M&A activities.

Corporate Governance

Related Party Transactions

• Grant of 9,321 Restricted Stock Units to Eliav Barr, a director of Veracyte, Inc., as part of standard equity compensation.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making and value creation.
• Employees: No direct impact on employees mentioned in this filing.

Next Steps

• Vesting of the 9,321 Restricted Stock Units on June 18, 2026, or earlier, based on the specified conditions.
• The Company's next annual meeting of stockholders, which could trigger earlier vesting of the RSUs.

Key Dates

Keywords

Veracyte, VCYT, Eliav Barr, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Grant, SEC Form 4, Beneficial Ownership